Immunosuppressive regimens containing generic mycophenolate mofetil (Myfenax) in de novo renal transplant recipients - preliminary results of 6-month observation

Annals of Transplantation

Volumn 16, Issue 4, 2011, Pages 74-80

  Rutkowski, BolesŁaw ^a   Bzoma, Beata ^a   Debska Ślizień, Alicja ^a   Chamienia, Andrzej ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Kidney transplantation; Mycophenolate mofetil; Myfenax

Indexed keywords

APOTEX; CREATININE; CYCLOSPORIN; GENERIC DRUG; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DELAYED GRAFT FUNCTION; DRUG DOSE REDUCTION; DRUG FORMULATION; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; TREATMENT OUTCOME;

EID: 84855475777     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.882222     Document Type: Article

References (21)

1. European Mycophenolate Mofetil Study group: Placebo-controlled study of mycophenoate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet, 1995; 345: 1321-25
2. Tricontinental Mycophenolate Mofetil renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation, 1996; 61: 1029-37
3. US Renal Transplant Mycophenolate Mofetil Study Group, Sollinger H: Mycophenolate Mofetil for acute rejection in primary cadaveric renal allograft recipients. Transplantation, 1995; 60: 225-32
4. The International Mycophenolate Mofetil Renal Trasplant Study Groups, Halloran P, Mathew T, Tomlanovich S et al: Mycophenolate mofetil in renal allograft recipients: a polled efficacy analysis of three randomized, double-blind clinical studies in prevention of rejection. Transplantation, 1997; 63: 39-47
5. Mycophenolate Mofetil Acute Renal Rejection Study Group: Mycophenolate mofetil for the treatment of a first acute renal allograft rejection. Transplantation, 1998; 65: 235-41
6. Ojo A, Meier-Kriesche H, Hanson J et al: Mycophenolate mofetil reduces late renal allograft loss independently of acute rejection. Transplantation, 2000; 69(11): 2405-9
7. Remuzzi G, Lesti M, Gotti E et al: Mycophenolate mofetil versus azatioprine for prevention of acute rejection in renal transplantation (MYSS): A randomized trial. Lancet, 2004; 354: 503-12
8. Remuzzi G, Cravedi P, Costantini M et al: Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol, 2007; 18: 1973-85
9. Ekberg H, Tedesco-Silva H, Demirbas A et al: ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med, 2007; 357(25): 2562-75
10. Squifflet J, Vanrenterghem Y, van Hooff J et al: Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter study. Transplantation Proceedings, 2002; 34(5): 1584-86
11. Matas AJ, Ramcharan T, Paraskevas S et al: Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant, 2001; 1(3): 278-83
12. Masri MA, Andrysek T, Rizk S et al: The Role of Generics in Transplantation: TM-MMF Versus Cellcept in Healthy Volunteers. Transplantation Proceedings, 2004; 36: 84-85
13. Holt D: Generic Formulations of Immunosuppressive. Is it always safe to swith? Ann Transplant, 2009; 14(Suppl.1): 11
14. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transpl, 2009; 9(Suppl.3): s20
15. Gonwa T, Johnson C, Ahsan N et al: Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation, 2003; 75(12): 2048-53
16. Albano L, Bretagne S, Mamzer-Bruneel MF et al: Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin Infect Dis, 2009; 48(2): 194-202
17. Sorto R, Irizar SS, Gelgadilo G et al: Risk factors for urinary tract infections during the first year after kidney transplantation. Transplant Proc, 2010; 42: 280-81
18. Veroux M, Giuffrida G, Corona D et al: Infective complications in renal allograft recipients: epidemiology and outcome. Transplant Proc, 2008; 40: 1873-76
19. Hardinger K, Brennan D, Lowell J et al: Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int, 2004; 17(10): 609-16
20. Pelletier R, Akin B, Henry M et al: The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant, 2003; 17(3): 200-5
21. Tierce J, Porterfield-Baxa J, Petrilla A et al: Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant, 2005; 19(6): 779-84